https://www.pharmaradar360.com/article/vivani-medical-receives-regulatory-approval-for-the-initiation-of-slim-1-a-phase-8a04eac5ac69378cPharma Surgeen2026-06-25T11:30:00.000ZVivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Managementhttps://www.pharmaradar360.com/article/as-compounding-pharmacies-expand-patients-are-left-in-the-dark-about-drug-risks-994a866a7284bd85Pharma Surgeen2026-06-25T11:07:06.000ZAs compounding pharmacies expand, patients are left in the dark about drug riskshttps://www.pharmaradar360.com/article/tiziana-announces-last-patient-successfully-dosed-in-its-phase-2-inform-ms-trial-776d6941dd04ed0aPharma Surgeen2026-06-25T11:00:00.000ZTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trialhttps://www.pharmaradar360.com/article/eledon-trial-will-use-natera-s-prospera-test-to-track-kidney-rejection-0c1cf7019f6f19edPharma Surgeen2026-06-25T11:00:00.000ZEledon trial will use Natera’s Prospera test to track kidney rejectionhttps://www.pharmaradar360.com/article/atea-enrolls-880-plus-patients-in-global-hepatitis-c-trial-71a02ca3a6199edbPharma Surgeen2026-06-25T11:00:00.000ZAtea enrolls 880-plus patients in global hepatitis C trialhttps://www.pharmaradar360.com/article/natera-and-eledon-announce-strategic-partnership-for-prosperatm-monitoring-in-pl-8c0a1e393608c3b4Pharma Surgeen2026-06-25T11:00:00.000ZNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trialhttps://www.pharmaradar360.com/article/ionis-bags-30m-from-recordati-for-ex-us-rights-to-near-approval-rare-disease-pro-42847fcec46f2aa0Pharma Surgeen2026-06-25T10:59:22.000ZIonis bags $30M from Recordati for ex-US rights to near-approval rare disease prospecthttps://www.pharmaradar360.com/article/adc-therapeutics-cuts-jobs-as-zynlonta-fda-talks-loom-0da62cecfc556d61Pharma Surgeen2026-06-25T10:46:37.000ZADC Therapeutics cuts jobs as Zynlonta FDA talks loomhttps://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-9e3103fd262e9ca3Pharma Surgeen2026-06-25T10:45:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)https://www.pharmaradar360.com/article/what-medicare-part-d-patients-need-to-know-about-accessing-foundayo-orforglipron-495b5bc0715962aePharma Surgeen2026-06-25T10:45:00.000ZWhat Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementhttps://www.pharmaradar360.com/article/julie-kim-takes-top-job-at-takeda-after-weber-retirement-b4180ad723a22828Pharma Surgeen2026-06-25T10:36:34.000ZJulie Kim takes top job at Takeda after Weber retirementhttps://www.pharmaradar360.com/article/the-realities-of-pharmaceutical-onshoring-a-cdmo-perspective-11437428e84d4f58Pharma Surgeen2026-06-25T10:29:48.000ZThe realities of pharmaceutical onshoring: a CDMO perspectivehttps://www.pharmaradar360.com/article/helus-pharma-help-prices-us-50m-share-sale-to-fund-phase-3-mdd-trial-d8ea228dd4ec6ea8Pharma Surgeen2026-06-25T10:28:24.000ZHelus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trialhttps://www.pharmaradar360.com/article/highs-and-lows-u-s-drug-prices-in-2025-30c6b0553826f540Pharma Surgeen2026-06-25T10:01:51.000ZHighs and Lows: U.S. Drug Prices in 2025https://www.pharmaradar360.com/article/bio-usa-abl-bio-ceo-sanghoon-lee-phase-3-gastric-cancer-drug-trial-to-begin-this-5a89a7f321c30232Pharma Surgeen2026-06-25T09:49:46.000Z[BIO USA] ABL Bio CEO Sanghoon Lee: "Phase 3 Gastric Cancer Drug Trial to Begin This Year"https://www.pharmaradar360.com/article/yomiuri-takeda-pharmaceutical-s-weber-says-company-in-good-position-for-the-futu-047136d64315ff33Pharma Surgeen2026-06-25T09:48:00.000ZYomiuri: Takeda Pharmaceutical's Weber Says Company in 'Good Position for the Future' As He Steps Downhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-rtw-biotech-opportunities-ltd-usd-fwb-0bm-c2077f82544a2b0dPharma Surgeen2026-06-25T09:46:44.000ZPrice to sales forward of RTW Biotech Opportunities Ltd USD – FWB:0BMhttps://www.pharmaradar360.com/article/price-to-book-forward-of-biomarin-pharmaceutical-inc-gettex-bm8-3ee4a9848c61c8c4Pharma Surgeen2026-06-25T09:45:48.000ZPrice to book forward of BioMarin Pharmaceutical Inc. – GETTEX:BM8https://www.pharmaradar360.com/article/price-to-book-forward-of-feng-chi-biotech-corp-tpex-6744-77fa59a7cbfb2d98Pharma Surgeen2026-06-25T09:45:23.000ZPrice to book forward of Feng Chi Biotech Corp. – TPEX:6744https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-krystal-biotech-inc-nasdaq-krys-54c6a4113e936644Pharma Surgeen2026-06-25T09:34:32.000ZEnterprise value to revenue forward of Krystal Biotech, Inc. – NASDAQ:KRYShttps://www.pharmaradar360.com/article/pharmaceutical-regulatory-update-2026-eu-uk-fda-global-changes-explained-729ffc5c9f68e41cPharma Surgeen2026-06-25T09:34:02.000ZPharmaceutical regulatory update 2026: EU, UK, FDA & global changes explainedhttps://www.pharmaradar360.com/article/guidance-mhra-innovation-office-guidance-and-support-d55aaa5713ffae60Pharma Surgeen2026-06-25T09:16:18.000ZGuidance: MHRA Innovation Office: guidance and supporthttps://www.pharmaradar360.com/article/tracking-cathie-wood-major-ai-biotech-discovery-bet-on-recursion-heavy-reduction-513492f11d900cbePharma Surgeen2026-06-25T09:03:26.000ZTracking Cathie Wood: Major AI Biotech Discovery Bet on Recursion, Heavy Reduction in Absci Holdingshttps://www.pharmaradar360.com/article/bio-2026-how-nih-cuts-have-threatened-us-competitiveness-against-china-b4bc17e6dfc4e7caPharma Surgeen2026-06-25T09:00:00.000ZBIO 2026: How NIH cuts have threatened US competitiveness against Chinahttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stake-increased-by-sg-americas-securitie-4fddb2b2b48d6a0bPharma Surgeen2026-06-25T08:55:10.000ZTeva Pharmaceutical Industries Ltd. $TEVA Stake Increased by SG Americas Securities LLChttps://www.pharmaradar360.com/article/bio-2026-indiana-biopharma-investment-and-the-lilly-effect-2c0308532361277ePharma Surgeen2026-06-25T08:53:04.000ZBIO 2026: Indiana, biopharma investment and the Lilly effecthttps://www.pharmaradar360.com/article/abl-bio-is-launching-phase-3-global-clinical-trials-of-its-new-gastric-cancer-dr-0a6fe21423b25f84Pharma Surgeen2026-06-25T08:50:09.000ZABL Bio is launching phase 3 global clinical trials of its new gastric cancer drug "ABL111" within t..https://www.pharmaradar360.com/article/vaccine-schedule-change-helps-protect-babies-earlier-against-meningitis-b-9d70be5a1c71dee4Pharma Surgeen2026-06-25T08:50:00.000ZVaccine schedule change helps protect babies earlier against meningitis Bhttps://www.pharmaradar360.com/article/biosecure-didn-t-stop-china-s-rise-in-biotech-some-lawmakers-want-to-do-more-f301323cecb6df92Pharma Surgeen2026-06-25T08:30:49.000ZBiosecure didn’t stop China’s rise in biotech. Some lawmakers want to do morehttps://www.pharmaradar360.com/article/hsbc-holdings-plc-lowers-holdings-in-teva-pharmaceutical-industries-ltd-teva-7c8039a60abac925Pharma Surgeen2026-06-25T08:30:14.000ZHsbc Holdings PLC Lowers Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-06-25T08:30:11.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-06-25T08:30:11.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-06-25T08:30:11.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-06-25T08:30:11.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/tetanus-in-england-annual-reports-55f6cea4b8ae62acPharma Surgeen2026-06-25T08:30:06.000ZTetanus in England: annual reportshttps://www.pharmaradar360.com/article/pertussis-laboratory-confirmed-cases-reported-in-england-2025-aad4dec619bb9eebPharma Surgeen2026-06-25T08:30:06.000ZPertussis: laboratory confirmed cases reported in England 2025https://www.pharmaradar360.com/article/fungaemia-including-candidaemia-annual-data-from-voluntary-surveillance-edab4d6534b55584Pharma Surgeen2026-06-25T08:30:05.000ZFungaemia (including candidaemia): annual data from voluntary surveillancehttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9Pharma Surgeen2026-06-25T08:30:04.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/epidemiology-of-covid-19-in-england-42b3d6340228a3a1Pharma Surgeen2026-06-25T08:30:01.000ZEpidemiology of COVID-19 in Englandhttps://www.pharmaradar360.com/article/childhood-vaccination-coverage-provisional-monthly-data-for-england-096cd364d32970b8Pharma Surgeen2026-06-25T08:30:00.000ZChildhood vaccination coverage: provisional monthly data for Englandhttps://www.pharmaradar360.com/article/record-hk-delegation-showcases-life-sciences-edge-in-san-diego-d2fe7fddc7b7a210Pharma Surgeen2026-06-25T08:12:28.000ZRecord HK delegation showcases life sciences edge in San Diegohttps://www.pharmaradar360.com/article/barometre-360-de-l-attractivite-de-la-france-pour-l-industrie-pharmaceutique-edi-19ff4524e0f1f3cbPharma Surgeen2026-06-25T08:12:20.000ZBaromètre 360° de l’attractivité de la France pour l’industrie pharmaceutique - Edition 2026 : Accès aux traitements, progrès thérapeutique, attractivité de la France : reprendre l’avantage ou décrocher ?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-biomarin-pharmaceutical-inc-nasdaq-bmrn-07de7e9244ed0d80Pharma Surgeen2026-06-25T08:07:27.000ZEnterprise value to EBITDA forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRNhttps://www.pharmaradar360.com/article/can-restaurants-charge-you-for-drinking-water-maharashtra-fda-s-new-order-says-71de6bd0b9d2b43bPharma Surgeen2026-06-25T07:58:59.000ZCan Restaurants Charge You For Drinking Water? Maharashtra FDA’s New Order Says…https://www.pharmaradar360.com/article/ipsen-recognized-at-lten-excellence-awards-2026-for-transforming-field-leadershi-1629ad33c263ee6fPharma Surgeen2026-06-25T07:57:06.000ZIpsen recognized at LTEN Excellence Awards 2026 for transforming field leadership through coachinghttps://www.pharmaradar360.com/article/are-you-working-with-cell-therapy-and-planning-a-clinical-trial-fa8ac360a3c2413fPharma Surgeen2026-06-25T07:52:00.000ZAre you working with cell therapy and planning a clinical trial?https://www.pharmaradar360.com/article/east-asia-s-biotech-autonomy-push-is-already-stunting-innovation-808f966407a0c507Pharma Surgeen2026-06-25T07:37:11.000ZEast Asia’s biotech autonomy push is already stunting innovationhttps://www.pharmaradar360.com/article/zepzelca-8340fbf8b145e16dPharma Surgeen2026-06-25T07:12:30.000ZZepzelcahttps://www.pharmaradar360.com/article/jazz-pharmaceuticals-zepzelca-misses-primary-endpoint-in-phase-3-lung-cancer-tri-48295a4697676f4fPharma Surgeen2026-06-25T07:02:45.000ZJazz Pharmaceuticals Zepzelca Misses Primary Endpoint in Phase 3 Lung Cancer Trialhttps://www.pharmaradar360.com/article/recordati-announces-license-agreement-with-ionis-pharmaceuticals-for-zilganersen-7e85659ea7fd2290Pharma Surgeen2026-06-25T06:59:07.000ZRECORDATI ANNOUNCES LICENSE AGREEMENT WITH IONIS PHARMACEUTICALS FOR ZILGANERSEN FOR THE TREATMENT OF ALEXANDER DISEASE IN ALL COUNTRIES OUTSIDE THE U.S.https://www.pharmaradar360.com/article/fda-backs-entera-bio-s-phase-3-plan-for-oral-eb613-osteoporosis-drug-e2e36f34828d0b7ePharma Surgeen2026-06-25T06:53:04.000ZFDA Backs Entera Bio’s Phase 3 Plan for Oral EB613 Osteoporosis Drughttps://www.pharmaradar360.com/article/maharashtra-fda-bans-serving-food-in-newspapers-issues-statewide-food-safety-ord-b2a326d0eb8af15dPharma Surgeen2026-06-25T06:48:00.000ZMaharashtra FDA bans serving food in newspapers, issues statewide food safety orderhttps://www.pharmaradar360.com/article/eli-lilly-signs-new-partnership-deal-with-china-s-abbisko-84d661d5953aa368Pharma Surgeen2026-06-25T06:39:59.000ZEli Lilly signs new partnership deal with China's Abbiskohttps://www.pharmaradar360.com/article/matters-concerning-controlling-shareholders-etc-466420396ec1213cPharma Surgeen2026-06-25T06:30:00.000ZMatters Concerning Controlling Shareholders, Etc.https://www.pharmaradar360.com/article/atrasentan-06d83d835d0cce4bPharma Surgeen2026-06-25T06:27:51.000ZAtrasentanhttps://www.pharmaradar360.com/article/avacta-reports-platform-validating-data-with-faridoxorubicin-during-bio-internat-ab5b376dbfa750a1Pharma Surgeen2026-06-25T06:04:46.000ZAvacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conferencehttps://www.pharmaradar360.com/article/avacta-announces-u-s-fda-agreement-on-pivotal-trial-design-for-ava6000-in-patien-6d314ce54ca178b0Pharma Surgeen2026-06-25T06:02:40.000ZAvacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancerhttps://www.pharmaradar360.com/article/otsuka-announces-positive-phase-3b-results-for-centanafadine-in-adults-with-adhd-2a238bee4fc92a9fPharma Surgeen2026-06-25T06:00:00.000ZOtsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxietyhttps://www.pharmaradar360.com/article/bio-usa-korea-exchange-courts-global-biotech-ipos-at-bio-usa-434c7c1ea7a55566Pharma Surgeen2026-06-25T05:21:32.000Z[Bio USA] Korea Exchange courts global biotech IPOs at Bio USAhttps://www.pharmaradar360.com/article/comment-pharma-s-demand-for-innovation-is-powering-biotech-s-recovery-d502cdf52cfa4941Pharma Surgeen2026-06-25T05:17:06.000ZComment: Pharma’s demand for innovation is powering biotech’s recoveryhttps://www.pharmaradar360.com/article/al-s-pharma-presents-ap-101-phase-2-data-supporting-misfolded-sod1-as-a-therapeu-153ed301f5e7a41bPharma Surgeen2026-06-25T04:02:35.000ZAL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026https://www.pharmaradar360.com/article/patent-cliffs-aren-t-the-only-driver-of-the-biotech-m-a-boom-7473cfb85d33ed9aPharma Surgeen2026-06-25T04:02:00.000ZPatent cliffs aren’t the only driver of the biotech M&A boomhttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-9a3365a8933f4fddPharma Surgeen2026-06-25T01:50:46.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drughttps://www.pharmaradar360.com/article/abu-dhabi-doh-partners-with-biocom-california-on-biotech-2a6cd88195bf1d3ePharma Surgeen2026-06-25T01:17:44.000ZAbu Dhabi DoH Partners with Biocom California on Biotechhttps://www.pharmaradar360.com/article/bio-usa-2026-pangen-biotech-eyes-europe-as-next-market-for-epo-biosimilar-590506cb4f14bef4Pharma Surgeen2026-06-25T00:52:25.000Z[BIO USA 2026] PanGen Biotech eyes Europe as next market for EPO biosimilarhttps://www.pharmaradar360.com/article/taiho-pharmaceutical-earns-first-silver-medal-in-ecovadis-sustainability-rating-f23b7c5652ce5258Pharma Surgeen2026-06-25T00:00:00.000ZTaiho Pharmaceutical Earns First Silver Medal in EcoVadis Sustainability Ratinghttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-38990f832f1792baPharma Surgeen2026-06-25T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-a78d79b064f14712Pharma Surgeen2026-06-25T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-d6bb36896399f72fPharma Surgeen2026-06-25T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-352f0a13c1333c21Pharma Surgeen2026-06-25T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-50739d6e77ad7cb8Pharma Surgeen2026-06-25T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-559b2a045643cfbcPharma Surgeen2026-06-25T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b2d826273c9db290Pharma Surgeen2026-06-25T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-d01e00d3d8ac1a26Pharma Surgeen2026-06-25T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-63a35a9221716570Pharma Surgeen2026-06-25T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-531c1f532eb05ea4Pharma Surgeen2026-06-25T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-a0b0d57cb542e9abPharma Surgeen2026-06-25T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b4ca0ba71b2b7ce9Pharma Surgeen2026-06-25T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-29e0518b1873af45Pharma Surgeen2026-06-25T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-4c70fcf6a732f5b6Pharma Surgeen2026-06-25T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/sterigenics-u-s-llc-filing-of-food-additive-petition-bc472b5373fba08bPharma Surgeen2026-06-25T00:00:00.000ZSterigenics U.S., LLC; Filing of Food Additive Petitionhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-cf30b759aa9248fdPharma Surgeen2026-06-25T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/government-owned-inventions-available-for-license-c8166-45-cell-line-427447d67509dcd6Pharma Surgeen2026-06-25T00:00:00.000ZGovernment Owned Inventions Available for License: C8166-45 Cell Linehttps://www.pharmaradar360.com/article/government-owned-inventions-available-for-license-compositions-and-methods-for-p-92fb7a0282013563Pharma Surgeen2026-06-25T00:00:00.000ZGovernment Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacyhttps://www.pharmaradar360.com/article/proposed-information-collection-activity-national-and-state-survey-of-child-and-d57cf429230cd62cPharma Surgeen2026-06-25T00:00:00.000ZProposed Information Collection Activity; National and State Survey of Child and Adolescent Well-Being (NSSCAW): Site Recruitment and Baseline Data Collectionhttps://www.pharmaradar360.com/article/notice-of-proposed-purchased-referred-care-delivery-area-redesignation-for-the-k-33c1ade47720f715Pharma Surgeen2026-06-25T00:00:00.000ZNotice of Proposed Purchased/Referred Care Delivery Area Redesignation for the Kewa Pueblohttps://www.pharmaradar360.com/article/order-under-sections-362-and-365-of-the-public-health-service-act-continuing-the-0688b7bbae0eedc4Pharma Surgeen2026-06-25T00:00:00.000ZOrder Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Existshttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-85d408578e78ccf1Pharma Surgeen2026-06-25T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-2be17aa3a65e9432Pharma Surgeen2026-06-25T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/incidental-electrocardiographic-recognition-of-left-anterior-fascicular-block-wi-6d0c925cbd3cd0ebPharma Surgeen2026-06-25T00:00:00.000ZIncidental Electrocardiographic Recognition of Left Anterior Fascicular Block With Delayed Troponin Elevation: A Case Report With Clinical Correlationhttps://www.pharmaradar360.com/article/the-multifaceted-role-of-bile-acids-in-breast-cancer-pathogenesis-therapeutic-po-6b939b39bd8297b5Pharma Surgeen2026-06-25T00:00:00.000ZThe multifaceted role of bile acids in breast cancer: pathogenesis, therapeutic potential, and drug deliveryhttps://www.pharmaradar360.com/article/clinical-practice-guideline-of-pet-ct-and-pet-mr-in-lymphoma-2025-edition-93293b0e34a8336cPharma Surgeen2026-06-25T00:00:00.000ZClinical practice guideline of PET/CT and PET/MR in lymphoma (2025 edition)https://www.pharmaradar360.com/article/global-pharmaceutical-market-evolution-from-blockbuster-drugs-to-biologics-and-b-426ce81dfecbd711Pharma Surgeen2026-06-25T00:00:00.000ZGlobal Pharmaceutical Market Evolution: From Blockbuster Drugs to Biologics and Biosimilars – A Comprehensive Reviewhttps://www.pharmaradar360.com/article/harnessing-minimal-residual-disease-for-precision-medicine-in-locally-advanced-g-8445d72d01f197d5Pharma Surgeen2026-06-25T00:00:00.000ZHarnessing minimal residual disease for precision medicine in locally advanced gastric cancerhttps://www.pharmaradar360.com/article/effect-of-fusidic-acid-phonophoresis-as-a-complementary-therapy-in-chronic-rhino-530bb5b57a7611ccPharma Surgeen2026-06-25T00:00:00.000ZEffect of fusidic acid phonophoresis as a complementary therapy in chronic rhinosinusitis: a randomised clinical trialhttps://www.pharmaradar360.com/article/the-integration-of-new-technologies-in-diabetes-care-a-review-of-clinical-applic-20f24b31a8604791Pharma Surgeen2026-06-25T00:00:00.000ZTHE INTEGRATION OF NEW TECHNOLOGIES IN DIABETES CARE: A REVIEW OF CLINICAL APPLICATIONS AND OUTCOMEShttps://www.pharmaradar360.com/article/data-driven-clinical-phenotyping-of-adult-epilepsy-using-latent-class-analysis-a-36126bfe9c0c430aPharma Surgeen2026-06-25T00:00:00.000ZData-Driven Clinical Phenotyping of Adult Epilepsy Using Latent Class Analysis: A Regional Cohort Study from Southern Kazakhstanhttps://www.pharmaradar360.com/article/not-all-microbiomes-reflect-chronic-pain-evidence-from-the-urinary-tract-in-a-ca-e0e933564f902305Pharma Surgeen2026-06-25T00:00:00.000ZNot All Microbiomes Reflect Chronic Pain: Evidence from the Urinary Tract in a Case–Control Studyhttps://www.pharmaradar360.com/article/dynamic-voice-optimization-after-type-i-thyroplasty-using-a-novel-adjustable-imp-bd534c20b5d8221cPharma Surgeen2026-06-25T00:00:00.000ZDynamic Voice Optimization After Type I Thyroplasty Using a Novel Adjustable Implant: A Prospective Longitudinal Studyhttps://www.pharmaradar360.com/article/sedentarism-exhibits-a-distinct-mitochondrial-bioenergetic-phenotype-detectable-92463f7952f2a487Pharma Surgeen2026-06-25T00:00:00.000ZSedentarism Exhibits a Distinct Mitochondrial Bioenergetic Phenotype Detectable by Cardiopulmonary Exercise and Lactate Testing (CPELT)https://www.pharmaradar360.com/article/trial-of-fasteddy-simulation-of-building-induced-airflow-and-the-comparison-with-bbe8f0523c91021dPharma Surgeen2026-06-25T00:00:00.000ZTrial of FastEddy Simulation of Building-Induced Airflow and the Comparison with LIDAR and Flight Data in an Operating Airporthttps://www.pharmaradar360.com/article/k-anonymity-decay-in-multi-turn-clinical-large-language-model-conversations-29d79348ad2a68acPharma Surgeen2026-06-25T00:00:00.000ZK-anonymity decay in multi-turn clinical large language model conversationshttps://www.pharmaradar360.com/article/chronic-viral-hepatitis-with-concurrent-masld-dual-etiology-challenges-f6acd75936a77d08Pharma Surgeen2026-06-25T00:00:00.000ZChronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challengeshttps://www.pharmaradar360.com/article/clinical-utility-of-liquid-biopsy-in-biliary-tract-cancer-diagnosis-to-treatment-95dee60488f87c55Pharma Surgeen2026-06-25T00:00:00.000ZClinical utility of liquid biopsy in biliary tract cancer: Diagnosis to treatment monitoringhttps://www.pharmaradar360.com/article/peer-review-report-for-viral-hepatitis-and-liver-disease-in-the-mongolian-commun-cec885b18e220cbaPharma Surgeen2026-06-25T00:00:00.000ZPeer Review Report For: Viral hepatitis and liver disease in the Mongolian community in London ('MoLo'): A mixed methods study protocol to investigate the epidemiology and burden of disease to inform clinical and public health interventions [version 1; peer review: 2 approved]https://www.pharmaradar360.com/article/prediction-model-for-severe-complications-in-patients-with-failed-conservative-t-6349b9a9c94dcc1cPharma Surgeen2026-06-25T00:00:00.000ZPrediction Model for Severe Complications in Patients with Failed Conservative Treatment of Acute Intestinal Obstruction Based on Clinical and Imaging Features: Development and Validationhttps://www.pharmaradar360.com/article/clinical-pharmacology-of-heart-failure-in-frailty-0dd3bd3632b0a513Pharma Surgeen2026-06-25T00:00:00.000ZClinical Pharmacology of Heart Failure in Frailtyhttps://www.pharmaradar360.com/article/management-of-catatonia-in-parkinson-s-disease-with-comorbid-bipolar-disorder-a-4f6074542e9aed24Pharma Surgeen2026-06-25T00:00:00.000ZManagement of catatonia in Parkinson’s disease with comorbid bipolar disorder: A case report and review of literaturehttps://www.pharmaradar360.com/article/pharmaceutical-import-landscape-in-ethiopia-a-cross-sectional-study-of-importers-2601ad284ca57be3Pharma Surgeen2026-06-25T00:00:00.000ZPharmaceutical import landscape in Ethiopia: a cross-sectional study of importers’ perspectives on business and regulatory challengeshttps://www.pharmaradar360.com/article/pre-emptive-treatment-in-later-onset-urea-cycle-disorders-a-clinical-perspective-bab37f6a8edafdeaPharma Surgeen2026-06-25T00:00:00.000ZPre-emptive treatment in later-onset urea cycle disorders: a clinical perspective on glycerol phenylbutyratehttps://www.pharmaradar360.com/article/fibroblast-activity-biomarkers-are-associated-with-mortality-in-severe-covid-19-f0a3f053109b2d9fPharma Surgeen2026-06-25T00:00:00.000ZFibroblast activity biomarkers are associated with mortality in severe COVID-19: a post-hoc analysis of a phase 2 clinical trialhttps://www.pharmaradar360.com/article/associations-of-anthropometric-related-phenotypes-with-functional-and-clinical-o-4a1a24d6487a7a93Pharma Surgeen2026-06-25T00:00:00.000ZAssociations of anthropometric-related phenotypes with functional and clinical outcomes in community-dwelling older adults: a cross-sectional analysis of ELSI-Brazilhttps://www.pharmaradar360.com/article/medical-student-experience-with-an-8-week-online-mindfulness-training-program-qu-7d9cfccbd29af109Pharma Surgeen2026-06-25T00:00:00.000ZMedical student experience with an 8-week online mindfulness training program: Qualitative findings from a mixed-method randomised controlled trialhttps://www.pharmaradar360.com/article/effectiveness-of-a-chronic-care-model-based-transitional-care-program-for-patien-65dbc28a8bd5ffb2Pharma Surgeen2026-06-25T00:00:00.000ZEffectiveness of a chronic care model-based transitional care program for patients with biliary drainage: a randomized controlled trialhttps://www.pharmaradar360.com/article/less-is-more-an-analysis-of-postoperative-outcomes-comparing-low-dose-e-coli-der-21fc9c746a5baf04Pharma Surgeen2026-06-25T00:00:00.000ZLess Is More! An Analysis of Postoperative Outcomes Comparing Low-Dose E. Coli-Derived rhBMP-2 and Mammalian rhBMP-2 in Lateral Lumbar Spinal Fusion Surgeryhttps://www.pharmaradar360.com/article/start-stop-amp-select-the-steward-s-hat-trick-9339f70ac6f680f1Pharma Surgeen2026-06-25T00:00:00.000ZStart, Stop &amp; Select: The Steward's Hat Trickhttps://www.pharmaradar360.com/article/interrelating-strategy-and-architecture-moves-a-clinical-inquiry-into-a-strategi-e303166497a4e5c7Pharma Surgeen2026-06-25T00:00:00.000ZInterrelating strategy and architecture moves: a clinical inquiry into a strategic digital initiativehttps://www.pharmaradar360.com/article/comparison-of-radiation-exposure-on-the-control-panel-side-versus-the-opposite-s-74988726fa743654Pharma Surgeen2026-06-25T00:00:00.000ZComparison of Radiation Exposure on the Control Panel Side Versus the Opposite Side During C-Arm Fluoroscopy-Guided Blocks: Randomized Controlled Trialhttps://www.pharmaradar360.com/article/a-nationwide-histopathology-study-reflecting-the-impact-of-the-introduction-of-m-1ed5235830cca92cPharma Surgeen2026-06-25T00:00:00.000ZA nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical carehttps://www.pharmaradar360.com/article/management-of-venous-thromboembolism-in-france-a-nationwide-clinical-practice-su-94cf9999514b7733Pharma Surgeen2026-06-25T00:00:00.000ZManagement of venous thromboembolism in France – a nationwide clinical practice survey among vascular medicine specialistshttps://www.pharmaradar360.com/article/associations-of-length-of-stay-with-sarcopenia-parameters-in-geriatric-patients-8b59535c257ea729Pharma Surgeen2026-06-25T00:00:00.000ZAssociations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest oldhttps://www.pharmaradar360.com/article/tumor-organoid-platform-design-for-drug-response-modeling-culture-architecture-m-14be896b81287737Pharma Surgeen2026-06-25T00:00:00.000ZTumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readoutshttps://www.pharmaradar360.com/article/cone-beam-computed-tomography-based-oropharyngeal-airway-narrowing-assessment-a-3fb6987c5a34d0ecPharma Surgeen2026-06-25T00:00:00.000ZCone-Beam Computed Tomography-Based Oropharyngeal Airway Narrowing Assessment: A Systematic Review of Methodologies, Measurements, and Clinical Associationshttps://www.pharmaradar360.com/article/out-of-field-and-in-field-teachers-professional-learning-gains-on-fostering-unde-4579f7c8520ce7caPharma Surgeen2026-06-25T00:00:00.000ZOut-of-field and in-field teachers’ professional learning gains on fostering understanding of multiplication: A randomized controlled trialhttps://www.pharmaradar360.com/article/surgical-strategies-and-long-term-survival-for-third-ventricle-chordoid-gliomas-a18bea32bb14a792Pharma Surgeen2026-06-25T00:00:00.000ZSurgical strategies and long-term survival for third ventricle chordoid gliomas: a systematic review and clinical algorithmhttps://www.pharmaradar360.com/article/effectiveness-of-low-level-laser-therapy-compared-to-standard-postoperative-care-fb51c48f8bccd6edPharma Surgeen2026-06-25T00:00:00.000ZEffectiveness of low-level laser therapy compared to standard postoperative care on pain intensity and cesarean section wound healing in the immediate postoperative period: a randomized clinical trialhttps://www.pharmaradar360.com/article/adjunctive-postoperative-vitamin-b-complex-with-ibuprofen-for-pain-and-soft-tiss-f6016f4f963808b3Pharma Surgeen2026-06-25T00:00:00.000ZAdjunctive postoperative vitamin B complex with ibuprofen for pain and soft-tissue healing after impacted mandibular third molar surgery: a split-mouth randomized clinical trialhttps://www.pharmaradar360.com/article/iridology-biological-plausibility-clinical-evidence-and-implications-for-ophthal-84241c297aa38011Pharma Surgeen2026-06-25T00:00:00.000ZIridology: Biological plausibility, clinical evidence, and implications for ophthalmic practicehttps://www.pharmaradar360.com/article/unveiling-dry-eye-disease-prior-to-cataract-surgery-a-multicenter-clinical-study-1bc5250a09c94136Pharma Surgeen2026-06-25T00:00:00.000ZUnveiling dry eye disease prior to cataract surgery: A multicenter clinical studyhttps://www.pharmaradar360.com/article/the-biotech-founder-asking-why-good-science-gets-stuck-c66cdcc4fc783570Pharma Surgeen2026-06-24T22:29:58.000ZThe biotech founder asking why good science gets stuckhttps://www.pharmaradar360.com/article/drug-maker-sues-to-halt-implementation-of-arkansas-new-pharmaceutical-distributi-8f8f4fa7e404a914Pharma Surgeen2026-06-24T21:25:00.000ZDrug maker sues to halt implementation of Arkansas’ new pharmaceutical distribution lawhttps://www.pharmaradar360.com/article/the-challenges-bringing-pharma-and-biotech-manufacturing-back-to-the-u-s-cf9dfcb0d97474efPharma Surgeen2026-06-24T21:21:57.000ZThe Challenges Bringing Pharma and Biotech Manufacturing Back to the U.S.https://www.pharmaradar360.com/article/results-that-matter-co-creating-individual-study-data-reports-with-patients-45777d14f77c8058Pharma Surgeen2026-06-24T21:03:19.000ZResults that Matter: Co-Creating Individual Study Data Reports With Patientshttps://www.pharmaradar360.com/article/news-australian-firm-lends-boost-to-boston-biotech-market-with-hq-deal-3d2c5ac026dc89b2Pharma Surgeen2026-06-24T21:01:17.000ZNews | Australian firm lends boost to Boston biotech market with HQ dealhttps://www.pharmaradar360.com/article/hlb-rallies-as-korea-bets-on-fda-liver-cancer-decision-amid-cmc-risks-chosunbiz-4a987de092dbef19Pharma Surgeen2026-06-24T21:01:00.000ZHLB rallies as Korea bets on FDA liver cancer decision amid CMC risks - CHOSUNBIZhttps://www.pharmaradar360.com/article/at-asms-2026-mass-spectrometry-stakes-its-claim-2b489495663fd000Pharma Surgeen2026-06-24T20:59:42.000ZAt ASMS 2026, mass spectrometry stakes its claimhttps://www.pharmaradar360.com/article/firm-advises-underwriters-on-legend-biotech-s-public-offering-6d10c7778755f32dPharma Surgeen2026-06-24T20:58:37.000ZFirm Advises Underwriters on Legend Biotech’s Public Offeringhttps://www.pharmaradar360.com/article/signs-of-recovery-in-the-biotech-industry-5547b5ca8f18525dPharma Surgeen2026-06-24T20:54:06.000ZSigns of Recovery in the Biotech Industryhttps://www.pharmaradar360.com/article/eli-lilly-and-abbisko-announce-drug-development-collaboration-pharmexec-7c713892bd147513Pharma Surgeen2026-06-24T20:38:10.000ZEli Lilly and Abbisko Announce Drug Development Collaboration | PharmExechttps://www.pharmaradar360.com/article/exozymes-awarded-2-million-nih-grant-to-advance-cannabinoid-analogs-for-drug-dis-1fbdcf63099fbf16Pharma Surgeen2026-06-24T20:07:19.000ZeXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discoveryhttps://www.pharmaradar360.com/article/hhs-proposes-clinical-trial-reform-to-catch-chinese-biotech-sector-0a23b6428df3b1afPharma Surgeen2026-06-24T19:55:59.000ZHHS Proposes Clinical Trial Reform To Catch Chinese Biotech Sectorhttps://www.pharmaradar360.com/article/bio-2026-ceo-calls-for-u-s-biotech-urgency-and-international-competitiveness-f8f871d4e91f3b22Pharma Surgeen2026-06-24T19:53:38.000ZBIO 2026: CEO Calls for U.S. Biotech Urgency and International Competitivenesshttps://www.pharmaradar360.com/article/restaurant-menus-must-have-calorie-allergen-info-maharashtra-fda-8c04f4606deb1afdPharma Surgeen2026-06-24T19:11:00.000ZRestaurant menus must have calorie & allergen info: Maharashtra FDAhttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-partnerships-facilitating-antibody-discovery-and-ai-drug-d-28f4155f5ab104fcPharma Surgeen2026-06-24T18:29:35.000ZThe biotech bi-weekly: partnerships facilitating antibody discovery and AI drug developmenthttps://www.pharmaradar360.com/article/restaurant-license-suspended-cheese-analogue-sold-as-paneer-pune-fda-launches-cr-9076a6ca598acca5Pharma Surgeen2026-06-24T18:23:21.000ZRestaurant license suspended | Cheese analogue sold as paneer: Pune FDA launches crackdownhttps://www.pharmaradar360.com/article/how-a-drug-with-more-negative-than-positive-studies-won-fda-approval-f5e95544772a9b9bPharma Surgeen2026-06-24T18:01:38.000ZHow a Drug With More Negative Than Positive Studies Won FDA Approvalhttps://www.pharmaradar360.com/article/yellow-fever-global-f31c497d0f687d00Pharma Surgeen2026-06-24T18:00:00.000ZYellow fever - Globalhttps://www.pharmaradar360.com/article/lly-stock-down-as-fda-asks-for-more-safety-data-on-oral-obesity-pill-e002c6564c96427bPharma Surgeen2026-06-24T17:53:51.000ZLLY stock down as FDA asks for more safety data on oral obesity pillhttps://www.pharmaradar360.com/article/chemical-explosion-fire-reported-at-rockland-county-pharmaceutical-facility-9ff29e52add97bbdPharma Surgeen2026-06-24T17:45:00.000ZChemical explosion, fire reported at Rockland County pharmaceutical facilityhttps://www.pharmaradar360.com/article/interfarma-apresenta-estudo-sobre-avancos-da-pesquisa-clinica-no-brasil-pais-gan-98ce2026b553088ePharma Surgeen2026-06-24T17:38:02.000ZInterfarma apresenta estudo sobre avanços da pesquisa clinica no Brasil: país ganha posições importanteshttps://www.pharmaradar360.com/article/fda-approves-palbociclib-for-hr-her2-metastatic-breast-cancer-maintenance-1ab14dbd645932efPharma Surgeen2026-06-24T17:01:39.000ZFDA Approves Palbociclib for HR+/HER2+ Metastatic Breast Cancer Maintenancehttps://www.pharmaradar360.com/article/pfizer-advances-new-pediatric-pneumococcal-catch-up-vaccine-in-phase-3-trial-9cc6353448e2ee5aPharma Surgeen2026-06-24T16:50:23.000ZPfizer Advances New Pediatric Pneumococcal “Catch-Up” Vaccine in Phase 3 Trialhttps://www.pharmaradar360.com/article/explosion-happens-in-pharmaceutical-building-in-rockland-county-4b0dec375c4e7d88Pharma Surgeen2026-06-24T16:30:00.000ZExplosion happens in pharmaceutical building in Rockland Countyhttps://www.pharmaradar360.com/article/moulton-pledges-investments-in-biotech-affordable-housing-8a655ce5cb03bed5Pharma Surgeen2026-06-24T16:25:11.000ZMoulton pledges investments in biotech, affordable housinghttps://www.pharmaradar360.com/article/mycobacterium-chimaera-infections-linked-to-heater-cooler-units-60a23db6445013c2Pharma Surgeen2026-06-24T16:21:02.000ZMycobacterium chimaera: infections linked to heater cooler unitshttps://www.pharmaradar360.com/article/foreign-secretary-announces-support-for-gaza-with-new-child-medical-evacuations-e6dcf7853d8be341Pharma Surgeen2026-06-24T15:48:52.000ZForeign Secretary announces support for Gaza with new child medical evacuations and assistance to Palestinians going to top UK universitieshttps://www.pharmaradar360.com/article/semaglutide-surge-associated-with-spike-in-poison-control-calls-9281278bc843d0b5Pharma Surgeen2026-06-24T15:48:47.000ZSemaglutide Surge Associated With Spike in Poison Control Callshttps://www.pharmaradar360.com/article/a-dispatch-on-ai-from-biotech-s-big-summer-bash-cb3d3b73dd6c4f90Pharma Surgeen2026-06-24T15:45:11.000ZA dispatch on AI from BIOtech’s big summer bashhttps://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d0cb2f53bbf31f42Pharma Surgeen2026-06-24T15:30:09.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/fda-complete-response-letter-crl-explained-what-it-means-for-biotech-stocks-7427cea75a999a61Pharma Surgeen2026-06-24T15:12:00.000ZFDA Complete Response Letter (CRL) Explained: What It Means For Biotech Stockshttps://www.pharmaradar360.com/article/general-medical-services-statement-of-financial-entitlements-directions-4a85d169127d6c46Pharma Surgeen2026-06-24T15:10:36.000ZGeneral Medical Services Statement of Financial Entitlements Directionshttps://www.pharmaradar360.com/article/physician-views-preview-sanofi-secures-european-approval-for-tolebrutinib-in-und-77eab8584c5238afPharma Surgeen2026-06-24T15:09:34.000ZPhysician Views Preview: Sanofi secures European approval for tolebrutinib in underserved MS populationhttps://www.pharmaradar360.com/article/what-parents-should-know-about-generic-drugs-308c8b4c7a5c7305Pharma Surgeen2026-06-24T15:02:45.000ZWhat Parents Should Know About Generic Drugshttps://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2Pharma Surgeen2026-06-24T14:51:32.000ZUKHSA spend over £25,000: 2026https://www.pharmaradar360.com/article/ukhsa-extends-red-heat-health-alerts-across-england-3ab1f8a5ec9bfc1dPharma Surgeen2026-06-24T14:47:03.000ZUKHSA extends red heat-health alerts across Englandhttps://www.pharmaradar360.com/article/haisco-and-nuvectis-sign-licensing-deal-for-two-drugs-a741fb23593958b6Pharma Surgeen2026-06-24T14:31:07.000ZHaisco and Nuvectis sign licensing deal for two drugshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-hits-52-week-high-at-338-73-61b58ce637bf150dPharma Surgeen2026-06-24T14:20:19.000ZWest Pharmaceutical Services stock hits 52-week high at $338.73https://www.pharmaradar360.com/article/news-pharmaceutical-giant-plans-more-than-1-billion-expansion-in-jacksonville-fl-b6b5ca31dd14d7b6Pharma Surgeen2026-06-24T14:19:51.000ZNews | Pharmaceutical giant plans more than $1 billion expansion in Jacksonville, Floridahttps://www.pharmaradar360.com/article/at-bio-a-glimpse-behind-lilly-and-chai-s-partnership-cef7fd9e504fd687Pharma Surgeen2026-06-24T14:14:53.000ZAt BIO, a glimpse behind Lilly and Chai’s partnershiphttps://www.pharmaradar360.com/article/drug-discovery-technologies-market-2026-2030-in-f8be93385467bd32Pharma Surgeen2026-06-24T14:09:42.000ZDrug Discovery Technologies Market 2026-2030 | Inhttps://www.pharmaradar360.com/article/london-biotech-biz-to-buy-cancer-focused-us-co-for-17m-5bd47ad64474c6b6Pharma Surgeen2026-06-24T14:09:00.000ZLondon Biotech Biz To Buy Cancer-Focused US Co. For £17Mhttps://www.pharmaradar360.com/article/6-biotech-stocks-that-delivered-stunning-gains-inbx-700-pvla-500-mbx-300-absi-20-8d75422a47ff2d5aPharma Surgeen2026-06-24T14:04:00.000Z6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & Morehttps://www.pharmaradar360.com/article/novartis-targets-undruggable-cancers-with-1-9bn-antares-therapeutics-deal-3b1a378e87b0d871Pharma Surgeen2026-06-24T14:03:00.000ZNovartis targets undruggable cancers with $1.9bn Antares Therapeutics dealhttps://www.pharmaradar360.com/article/endpoints-100-survey-biotech-ceos-predict-mfn-maneuvering-and-offer-a-few-ideas-7819886b423379a4Pharma Surgeen2026-06-24T14:00:00.000ZEndpoints 100 survey: Biotech CEOs predict MFN maneuvering and offer a few ideas for the FDAhttps://www.pharmaradar360.com/article/the-brown-capital-management-small-company-fund-bets-on-krystal-biotech-krys-for-60dbac6a0e45bdc5Pharma Surgeen2026-06-24T13:55:13.000ZThe Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Streamhttps://www.pharmaradar360.com/article/lundbeck-s-new-r-d-boss-welcomes-promotion-0d147d657f37ffb7Pharma Surgeen2026-06-24T13:15:57.000ZLundbeck's new R&D boss welcomes promotionhttps://www.pharmaradar360.com/article/jules-monneret-had-the-opportunity-to-explore-pharmaceutical-randd-at-servier-fr-29ac8df4c5a81261Pharma Surgeen2026-06-24T13:06:05.000ZJules Monneret: Had the Opportunity to Explore Pharmaceutical RandD at Servier Francehttps://www.pharmaradar360.com/article/abbott-pens-blood-based-alzheimer-s-testing-pact-with-alzpath-75f52fcd51abc0fdPharma Surgeen2026-06-24T13:02:46.000ZAbbott pens blood-based Alzheimer's testing pact with ALZpathhttps://www.pharmaradar360.com/article/roundtable-patient-services-leaders-on-the-pressures-shaping-hubs-in-2026-636d31aedc68b6f7Pharma Surgeen2026-06-24T12:57:09.000ZRoundtable: Patient Services Leaders on the Pressures Shaping Hubs in 2026https://www.pharmaradar360.com/article/osanni-bio-raises-190-million-series-b-to-advance-therapeutics-platform-8e795dc3dd934bcbPharma Surgeen2026-06-24T12:56:15.000ZOsanni Bio raises $190 million Series B to advance therapeutics platformhttps://www.pharmaradar360.com/article/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-treatments-fo-05025734047b39ebPharma Surgeen2026-06-24T12:45:00.000ZLilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordershttps://www.pharmaradar360.com/article/medicines-storage-needs-to-change-with-the-climate-f04ef057fea4d8d0Pharma Surgeen2026-06-24T12:41:05.000ZMedicines storage needs to change with the climatehttps://www.pharmaradar360.com/article/25-6-ddda2fbbc0a1b4cdPharma Surgeen2026-06-24T12:36:33.000Z(τελευταία ενημέρωση 25/6)ΑΝΑΚΟΙΝΩΣΗ – ΔΙΑΚΟΠΗ ΗΛΕΚΤΡΟΝΙΚΩΝ ΥΠΗΡΕΣΙΩΝhttps://www.pharmaradar360.com/article/finetech-debuts-fully-automatic-liquid-capsule-filling-machine-at-cphi-china-202-2e6f60087dbb9956Pharma Surgeen2026-06-24T12:36:12.000ZFinetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghaihttps://www.pharmaradar360.com/article/legionellosis-in-residents-of-england-and-wales-2025-ddbdab6f2a833e23Pharma Surgeen2026-06-24T12:29:15.000ZLegionellosis in residents of England and Wales: 2025https://www.pharmaradar360.com/article/martha-s-rule-extended-to-all-maternity-services-9101c6b1a3e571c1Pharma Surgeen2026-06-24T12:17:00.000ZMartha's Rule extended to all maternity serviceshttps://www.pharmaradar360.com/article/guidance-covid-19-test-validation-approved-products-af58b94cdba0a949Pharma Surgeen2026-06-24T12:16:57.000ZGuidance: COVID-19 test validation approved productshttps://www.pharmaradar360.com/article/viking-therapeutics-begins-phase-1-trial-of-weight-loss-drug-94b8f3781f12ac18Pharma Surgeen2026-06-24T12:05:46.000ZViking Therapeutics begins phase 1 trial of weight loss drughttps://www.pharmaradar360.com/article/notice-register-of-authorised-online-sellers-of-medicines-in-northern-ireland-a31b13f8e8d05b4ePharma Surgeen2026-06-24T12:01:27.000ZNotice: Register of authorised online sellers of medicines in Northern Irelandhttps://www.pharmaradar360.com/article/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc-ef6efcc7043085caPharma Surgeen2026-06-24T12:00:00.000ZGSK announces commencement of tender offer to acquire Nuvalent, Inc.https://www.pharmaradar360.com/article/uhi-4-high-flow-insufflation-system-insufflator-d040ec3b2ada59bePharma Surgeen2026-06-24T12:00:00.000ZUHI-4 High Flow Insufflation System - Insufflatorhttps://www.pharmaradar360.com/article/infiniontm-cx-contact-lead-kit-bc9b8fba9b9f7497Pharma Surgeen2026-06-24T12:00:00.000ZInfinion™ CX Contact Lead Kithttps://www.pharmaradar360.com/article/argon-medical-devices-l-cathtm-picc-and-midline-catheters-d54b717cf6cf435ePharma Surgeen2026-06-24T12:00:00.000ZArgon Medical Devices L-Cath™ PICC and Midline Cathetershttps://www.pharmaradar360.com/article/biotech-visionary-is-skeptical-about-ai-s-impact-on-medical-innovation-03981e96decca9d0Pharma Surgeen2026-06-24T12:00:00.000ZBiotech Visionary Is Skeptical About AI’s Impact on Medical Innovationhttps://www.pharmaradar360.com/article/botox-cosmetic-onabotulinumtoxina-introduces-the-confidence-collective-s-entrepr-1eef10263600357ePharma Surgeen2026-06-24T12:00:00.000ZBOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026https://www.pharmaradar360.com/article/insulet-hires-convatec-eli-lilly-alum-as-new-r-d-chief-56e5a2f5e7f0f4c7Pharma Surgeen2026-06-24T11:57:28.000ZInsulet hires Convatec, Eli Lilly alum as new R&D chiefhttps://www.pharmaradar360.com/article/after-apogee-3-more-biotech-buyout-targets-wall-street-can-t-stop-watching-4570c983a1db1d6fPharma Surgeen2026-06-24T11:55:10.000ZAfter Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watchinghttps://www.pharmaradar360.com/article/clostridioides-difficile-infection-how-to-deal-with-the-problem-160391dd74331fafPharma Surgeen2026-06-24T11:49:37.000ZClostridioides difficile infection: how to deal with the problemhttps://www.pharmaradar360.com/article/eli-lilly-reunites-with-abbisko-in-1-9b-multitarget-r-d-pact-12ac490e136f184aPharma Surgeen2026-06-24T11:47:46.000ZEli Lilly reunites with Abbisko in $1.9B, multitarget R&D pacthttps://www.pharmaradar360.com/article/unlocking-the-sustainability-data-inside-biotech-operations-53df70c1eabc86b1Pharma Surgeen2026-06-24T11:46:13.000ZUnlocking the Sustainability Data Inside Biotech Operationshttps://www.pharmaradar360.com/article/bio-2026-us-needs-to-dodge-china-s-inescapable-dependencies-to-protect-biotech-641507cd70ca8b4fPharma Surgeen2026-06-24T11:23:31.000ZBIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotechhttps://www.pharmaradar360.com/article/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress-8a40d76634fb17b2Pharma Surgeen2026-06-24T11:23:05.000ZHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progresshttps://www.pharmaradar360.com/article/drug-compounding-was-meant-for-individuals-empower-pharmacy-serves-70k-a-week-c7cc65d12a4e7763Pharma Surgeen2026-06-24T11:12:16.000ZDrug compounding was meant for individuals. Empower Pharmacy serves 70K a week.https://www.pharmaradar360.com/article/pharmacists-warn-of-uk-medicine-shortages-amid-us-drug-recall-370942b17ec1ea5aPharma Surgeen2026-06-24T11:10:21.000ZPharmacists warn of UK medicine shortages amid US drug recallhttps://www.pharmaradar360.com/article/ockenden-review-into-maternity-services-at-nottingham-university-hospitals-nhs-t-36fe922f80f82f6dPharma Surgeen2026-06-24T11:06:27.000ZOckenden review into maternity services at Nottingham University Hospitals NHS Trust: final reporthttps://www.pharmaradar360.com/article/viking-starts-first-human-test-of-vk3019-for-weight-loss-73007bc06b83a4b4Pharma Surgeen2026-06-24T11:05:00.000ZViking starts first human test of VK3019 for weight losshttps://www.pharmaradar360.com/article/ophthalmology-venture-grabs-investors-attention-raises-330-million-da66c414c437d06cPharma Surgeen2026-06-24T11:04:40.000ZOphthalmology venture grabs investors’ attention, raises $330 millionhttps://www.pharmaradar360.com/article/veraxa-adds-60-more-lab-space-in-heidelberg-for-cancer-drug-work-a5cd98c6364b3f8dPharma Surgeen2026-06-24T11:00:00.000ZVERAXA adds 60% more lab space in Heidelberg for cancer drug workhttps://www.pharmaradar360.com/article/fda-gives-calcimedica-no-comments-on-auxora-safety-review-b825359f44b822efPharma Surgeen2026-06-24T11:00:00.000ZFDA gives CalciMedica no comments on Auxora safety reviewhttps://www.pharmaradar360.com/article/ollin-hauls-in-330m-to-enlist-vabysmo-challenger-in-phase-3-eye-disease-gauntlet-d915e0de9d7fa235Pharma Surgeen2026-06-24T11:00:00.000ZOllin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlethttps://www.pharmaradar360.com/article/what-does-practical-sustainability-in-api-manufacturing-really-look-like-03e54795f2fc6509Pharma Surgeen2026-06-24T10:59:30.000ZWhat does practical sustainability in API manufacturing really look like?https://www.pharmaradar360.com/article/end-of-pilot-validation-learning-and-dissemination-event-of-the-2026-annual-mark-e485a56f854f7fc7Pharma Surgeen2026-06-24T10:51:00.000ZEnd-Of-Pilot Validation, Learning And Dissemination Event of The 2026 Annual Market-Level Large Scale Food Fortification (LSFF) Maiden Digital Monitoring And Compliance Surveyhttps://www.pharmaradar360.com/article/oura-and-lilly-join-forces-to-harmonise-drug-wearable-obesity-care-a8b25e8ea8fe1a57Pharma Surgeen2026-06-24T10:47:40.000ZŌURA and Lilly join forces to harmonise drug-wearable obesity carehttps://www.pharmaradar360.com/article/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedot-e83dd7d232ad217aPharma Surgeen2026-06-24T10:45:00.000ZEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-rises-wednesday-outperforms-competitors-99a03b79f1224b97Pharma Surgeen2026-06-24T10:32:00.000ZSun Pharmaceutical Industries rises Wednesday, outperforms competitorshttps://www.pharmaradar360.com/article/how-ups-is-adressing-pharmaceutical-procurement-challenges-1b0816db0394ea17Pharma Surgeen2026-06-24T10:08:07.000ZHow UPS is Adressing pharmaceutical Procurement Challengeshttps://www.pharmaradar360.com/article/helus-pharma-says-phase-3-depression-trial-is-86-enrolled-7486167422b33d49Pharma Surgeen2026-06-24T10:00:00.000ZHelus Pharma says Phase 3 depression trial is 86% enrolledhttps://www.pharmaradar360.com/article/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress-c5e27cbbb7c655e5Pharma Surgeen2026-06-24T10:00:00.000ZHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progresshttps://www.pharmaradar360.com/article/fda-cracks-down-on-counterfeit-cosmetics-illegal-drug-sales-fa788ec8b50e3098Pharma Surgeen2026-06-24T09:39:41.000ZFDA cracks down on counterfeit cosmetics, illegal drug saleshttps://www.pharmaradar360.com/article/the-new-drug-compound-that-could-treat-measles-outbreaks-and-other-viruses-9253f0753bedd2a9Pharma Surgeen2026-06-24T09:25:02.000ZThe new drug compound that could treat measles outbreaks – and other viruseshttps://www.pharmaradar360.com/article/corxel-s-oral-obesity-drug-clears-phase-ii-test-e7b35f5ebfeb9d53Pharma Surgeen2026-06-24T09:20:46.000ZCORXEL’s oral obesity drug clears Phase II testhttps://www.pharmaradar360.com/article/sangamo-files-for-bankruptcy-as-lilly-and-astellas-target-assets-22193f6d97baac4cPharma Surgeen2026-06-24T09:08:55.000ZSangamo files for bankruptcy as Lilly and Astellas target assetshttps://www.pharmaradar360.com/article/former-vertex-gsk-exec-launches-science-first-pet-nutrition-company-53f3d6ffcacd61d5Pharma Surgeen2026-06-24T09:08:00.000ZFormer Vertex, GSK exec launches science-first pet nutrition companyhttps://www.pharmaradar360.com/article/early-biomarkers-as-predictors-of-nephrology-trial-trajectory-c87dcbd28d59b554Pharma Surgeen2026-06-24T08:53:01.000ZEarly Biomarkers as Predictors of Nephrology Trial Trajectoryhttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0669-public-health-warning-against-the-purchase-and-use-of-98ee84a6ead8ffe4Pharma Surgeen2026-06-24T08:36:40.000ZFDA Advisory No.2026-0669 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Beauluck Tablet”https://www.pharmaradar360.com/article/the-things-to-think-about-before-taking-your-biotech-company-public-3472dda2cc6cc70fPharma Surgeen2026-06-24T07:50:03.000ZThe Things to Think About Before Taking Your Biotech Company Publichttps://www.pharmaradar360.com/article/usfda-rejects-achieve-s-smoking-cessation-drug-cytisinicline-over-manufacturing-677d50a1f8376f06Pharma Surgeen2026-06-24T07:30:13.000ZUSFDA Rejects Achieve's Smoking-Cessation Drug Cytisinicline Over Manufacturing Issueshttps://www.pharmaradar360.com/article/europe-approves-sanofi-s-multiple-sclerosis-drug-despite-fda-rejection-2624567edac00dcdPharma Surgeen2026-06-24T07:22:28.000ZEurope Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejectionhttps://www.pharmaradar360.com/article/pharmaceutical-omega-3-api-market-to-reach-usd-2-3-billion-by-2036-as-prescripti-83447f70072dadafPharma Surgeen2026-06-24T07:02:01.000ZPharmaceutical Omega-3 API Market to Reach USD 2.3 Billion by 2036 as Prescription Cardiovascular Therapies Drive Demand for High-Purity EPA APIs, FMIhttps://www.pharmaradar360.com/article/coiled-therapeutics-appoints-biotech-veteran-craig-tooman-to-board-1fc0eabf27f963a5Pharma Surgeen2026-06-24T06:56:00.000ZCoiled Therapeutics appoints biotech veteran Craig Tooman to boardhttps://www.pharmaradar360.com/article/revolution-medicines-opens-rasolute-305-trial-of-zoldonrasib-in-ras-g12d-pancrea-89d1548a6996ac96Pharma Surgeen2026-06-24T06:52:59.000ZRevolution Medicines Opens RASolute 305 Trial of Zoldonrasib in RAS G12D Pancreatic Cancerhttps://www.pharmaradar360.com/article/when-your-sponsor-gets-acquired-mid-trial-your-site-pays-the-operational-price-5d99f0b797d5c58fPharma Surgeen2026-06-24T06:52:59.000ZWhen Your Sponsor Gets Acquired Mid-Trial, Your Site Pays the Operational Pricehttps://www.pharmaradar360.com/article/first-aid-socialists-target-biotech-sweetener-64428c78af11f7e3Pharma Surgeen2026-06-24T06:52:03.000ZFIRST AID: Socialists target biotech sweetenerhttps://www.pharmaradar360.com/article/mckesson-selects-moore-oklahoma-for-179-million-state-of-the-art-pharmaceutical-fd5cf5e31cb48e12Pharma Surgeen2026-06-24T06:35:00.000ZMcKesson Selects Moore, Oklahoma for $179 Million State-of-the-Art Pharmaceutical Distribution Centerhttps://www.pharmaradar360.com/article/bio-usa-korean-biotech-has-innovation-now-it-needs-capital-13c2f930339dcaeaPharma Surgeen2026-06-24T06:30:11.000Z[Bio USA] Korean biotech has innovation. Now it needs capitalhttps://www.pharmaradar360.com/article/unixell-biotechnology-secures-fda-ind-clearance-for-ux-da003-achieving-china-u-s-8c07b39ee7bd7ce8Pharma Surgeen2026-06-24T06:25:22.000ZUniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapyhttps://www.pharmaradar360.com/article/pharma-ai-summer-update-preview-drive-the-future-of-pharmaceutical-intelligence-216a46d92fa7b3cfPharma Surgeen2026-06-24T05:23:42.000ZPharma.AI Summer Update Preview: Drive the future of pharmaceutical intelligencehttps://www.pharmaradar360.com/article/araris-biotech-ag-and-taiho-oncology-announce-dosing-of-first-patient-in-phase-1-524924865415451bPharma Surgeen2026-06-24T05:06:30.000ZAraris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphomahttps://www.pharmaradar360.com/article/reuters-health-news-summary-830b6b2e738c63e2Pharma Surgeen2026-06-24T04:59:21.000ZReuters Health News Summaryhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-pricey-as-glp-1-demand-lifts-expectations-c298653e5750d138Pharma Surgeen2026-06-24T04:57:22.000ZIs West Pharmaceutical Services (WST) Pricey As GLP 1 Demand Lifts Expectations?https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-stock-after-94-one-year-surge-is-the-price-j-3a182297afe4369ePharma Surgeen2026-06-24T03:28:00.000ZTeva Pharmaceutical Industries (TEVA) Stock After 94% One-Year Surge Is The Price Justifiedhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-seeks-10m-capital-injection-0d20182ec834882bPharma Surgeen2026-06-24T03:28:00.000ZRecce Pharmaceuticals seeks $10m capital injectionhttps://www.pharmaradar360.com/article/fda-backs-aft-s-injectable-iron-into-phase-3-study-as-company-targets-global-sca-76d8d198932e6eb3Pharma Surgeen2026-06-24T02:58:29.000ZFDA backs AFT’s injectable iron into Phase 3 study as company targets global scalehttps://www.pharmaradar360.com/article/pharmac-introduces-a-new-vision-and-strategic-priorities-640e013d777e6b11Pharma Surgeen2026-06-24T02:00:00.000ZPharmac introduces a new vision and strategic prioritieshttps://www.pharmaradar360.com/article/pharmac-funds-another-adhd-medicine-to-improve-supply-1ff120e85d863311Pharma Surgeen2026-06-24T02:00:00.000ZPharmac funds another ADHD medicine to improve supplyhttps://www.pharmaradar360.com/article/new-agreement-to-save-hospitals-millions-2c2ea1d39fa2ac7ePharma Surgeen2026-06-24T02:00:00.000ZNew agreement to save hospitals millionshttps://www.pharmaradar360.com/article/otsuka-america-establishes-the-pocari-sweat-science-advisory-boardannounces-new-cdb07cd89e3d2a03Pharma Surgeen2026-06-24T01:00:00.000ZOtsuka America Establishes the POCARI SWEAT SCIENCE ADVISORY BOARDAnnounces New Heat Illness Prevention Guidance to Address Heat Challenges in the United Stateshttps://www.pharmaradar360.com/article/global-pharma-leadership-voices-the-future-of-pharmaceutical-innovation-begins-w-60ee3994fa4ec79fPharma Surgeen2026-06-24T00:40:00.000Z[Global Pharma Leadership Voices] The future of pharmaceutical innovation begins where patients still waithttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-40300354bf791c91Pharma Surgeen2026-06-24T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-a060ee4bd6186914Pharma Surgeen2026-06-24T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-47384458a63ba5f3Pharma Surgeen2026-06-24T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/new-page-0c9db5ab105801ddPharma Surgeen2026-06-24T00:00:00.000Znew pagehttps://www.pharmaradar360.com/article/loyalty-petro-s-chili-chipstm-b874f3eaab0b7047Pharma Surgeen2026-06-24T00:00:00.000ZLoyalty — Petro's Chili & Chips™https://www.pharmaradar360.com/article/404-error-petro-s-chili-chipstm-8bc9ec0f329721c6Pharma Surgeen2026-06-24T00:00:00.000Z404 Error — Petro's Chili & Chips™https://www.pharmaradar360.com/article/new-treatment-option-recommended-for-recurrent-or-metastatic-cervical-cancer-eba35bc6e2bc0451Pharma Surgeen2026-06-24T00:00:00.000ZNew treatment option recommended for recurrent or metastatic cervical cancerhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-06-24T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-893712ea7fe33d49Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Chickens-Gallus Gallus; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-9bef3f045ec8bb7bPharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Felines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-4b2127e4ff8aa50ePharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Canines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-583c826a02c7beafPharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Porcines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-cae154bf8e2386e6Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Equines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-600224bd5b51ad56Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Caprines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-54092ff28d3b41e9Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Ovines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-25780f641f4d8a04Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Bovines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-31a2c3e7954c060ePharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: General Recommendations; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/medicare-and-state-health-care-programs-fraud-and-abuse-request-for-information-947a786c40a2498cPharma Surgeen2026-06-24T00:00:00.000ZMedicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMPhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-4520029496532faePharma Surgeen2026-06-24T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule Ihttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-bromazolam-in-schedule-i-correct-e44a3995822493b1Pharma Surgeen2026-06-24T00:00:00.000ZSchedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correctionhttps://www.pharmaradar360.com/article/amanda-ward-n-d-decision-and-order-e801daf927427c9aPharma Surgeen2026-06-24T00:00:00.000ZAmanda Ward, N.D.; Decision and Orderhttps://www.pharmaradar360.com/article/irina-gross-d-p-m-decision-and-order-74c76b404fcf3298Pharma Surgeen2026-06-24T00:00:00.000ZIrina Gross, D.P.M.; Decision and Orderhttps://www.pharmaradar360.com/article/fiscal-year-fy-2026-notice-of-supplemental-funding-opportunity-963d21b3c27713dePharma Surgeen2026-06-24T00:00:00.000ZFiscal Year (FY) 2026 Notice of Supplemental Funding Opportunityhttps://www.pharmaradar360.com/article/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biologica-08058812b8eab8c7Pharma Surgeen2026-06-24T00:00:00.000ZDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-d835e05efeee33d7Pharma Surgeen2026-06-24T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Informationhttps://www.pharmaradar360.com/article/master-protocols-for-drug-and-biological-product-development-draft-guidance-for-1fe1f9759aa3f262Pharma Surgeen2026-06-24T00:00:00.000ZMaster Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/quantitative-systems-pharmacology-qsp-based-dose-selection-for-minimum-anticipat-b46e928ff4245d85Pharma Surgeen2026-06-24T00:00:00.000ZQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-closed-meeting-1a544af7d7fe2ed5Pharma Surgeen2026-06-24T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/ars-pharmaceuticals-provides-commercial-and-financial-updates-925bce64e4317d5bPharma Surgeen2026-06-24T00:00:00.000ZARS Pharmaceuticals Provides Commercial and Financial Updateshttps://www.pharmaradar360.com/article/international-study-reveals-how-the-brain-senses-movement-bd14523e3beb1871Pharma Surgeen2026-06-24T00:00:00.000ZInternational Study Reveals How the Brain Senses Movementhttps://www.pharmaradar360.com/article/how-stress-can-impact-your-health-54421e37fe6ea16fPharma Surgeen2026-06-24T00:00:00.000ZHow Stress Can Impact Your Healthhttps://www.pharmaradar360.com/article/cleveland-clinic-completes-its-first-robotic-lung-transplant-in-u-s-a1562a09eb2cf3c2Pharma Surgeen2026-06-24T00:00:00.000ZCleveland Clinic Completes Its First Robotic Lung Transplant in U.S.https://www.pharmaradar360.com/article/critical-comments-by-the-european-medicines-agency-on-patient-reported-outcomes-95993db2f0ae0f7bPharma Surgeen2026-06-24T00:00:00.000ZCritical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).https://www.pharmaradar360.com/article/machine-learning-algorithms-to-predict-spray-dried-protein-peptide-formulations-856945f8ae9dff58Pharma Surgeen2026-06-24T00:00:00.000ZMachine learning algorithms to predict spray dried protein/peptide formulations.https://www.pharmaradar360.com/article/online-vs-in-person-care-for-atopic-dermatitis-a-randomized-clinical-trial-1839648bfb4eff54Pharma Surgeen2026-06-24T00:00:00.000ZOnline vs In-Person Care for Atopic Dermatitis: A Randomized Clinical Trial.https://www.pharmaradar360.com/article/novel-uveal-melanoma-patient-derived-cell-line-and-organoid-models-show-increase-262f85f745dcf3e8Pharma Surgeen2026-06-24T00:00:00.000ZNovel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines.https://www.pharmaradar360.com/article/anesthesia-strategy-and-clinical-outcomes-in-ruptured-aortic-aneurysm-repair-ins-1d6639903b916616Pharma Surgeen2026-06-24T00:00:00.000ZAnesthesia Strategy and Clinical Outcomes in Ruptured Aortic Aneurysm Repair: Insights from EVAR and TEVARhttps://www.pharmaradar360.com/article/multi-target-mechanism-of-action-of-curcumin-in-rheumatoid-arthritis-and-clinica-60acd8593ec02f49Pharma Surgeen2026-06-24T00:00:00.000ZMulti-target Mechanism of Action of Curcumin in Rheumatoid Arthritis and Clinical Applicationhttps://www.pharmaradar360.com/article/role-of-tumor-markers-and-cytokines-in-the-pathogenesis-of-lung-cancer-ce787bcfbc03f090Pharma Surgeen2026-06-24T00:00:00.000ZRole of tumor markers and cytokines in the pathogenesis of lung cancerhttps://www.pharmaradar360.com/article/prominent-crosstalks-between-perineural-invasion-and-immunosuppressive-tumor-mic-afe5af6ada1b347fPharma Surgeen2026-06-24T00:00:00.000ZProminent crosstalks between perineural invasion and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinomahttps://www.pharmaradar360.com/article/radiation-induced-cardiotoxicity-in-lung-cancer-current-landscape-and-future-dir-d87c06d8e2adf7d6Pharma Surgeen2026-06-24T00:00:00.000ZRadiation-induced cardiotoxicity in lung cancer: Current landscape and future directionshttps://www.pharmaradar360.com/article/letter-to-the-editor-yin-yang-1-in-inflammatory-memory-and-progression-susceptib-5055a860a59d8d08Pharma Surgeen2026-06-24T00:00:00.000ZLetter to the Editor: Yin Yang 1 in inflammatory memory and progression susceptibility in <i>Helicobacter pylori</i> –associated gastric cancerhttps://www.pharmaradar360.com/article/myo-inositol-and-d-chiro-inositol-in-polycystic-ovary-syndrome-mechanisms-of-act-da773c4ee911c586Pharma Surgeen2026-06-24T00:00:00.000ZMYO-INOSITOL AND D-CHIRO-INOSITOL IN POLYCYSTIC OVARY SYNDROME: MECHANISMS OF ACTION, CLINICAL EFFECTIVENESS, SAFETY, AND CURRENT LIMITATIONS: A NARRATIVE REVIEWhttps://www.pharmaradar360.com/article/effect-of-minimizing-light-exposure-with-digital-visualization-on-macular-functi-f8f9bc8f3ccfad66Pharma Surgeen2026-06-24T00:00:00.000ZEffect of Minimizing Light Exposure with Digital Visualization on Macular Function After Cataract Surgery in Patients with AMD: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-evaluation-of-a-combined-deep-learning-reconstructed-readout-segmented-467bf16bdca5a1b8Pharma Surgeen2026-06-24T00:00:00.000ZClinical Evaluation of a Combined Deep Learning–Reconstructed Readout-Segmented Echo-Planar Imaging and Water-Excitation Spectral Fat-Saturation Protocol for Breast Diffusion-Weighted Imaging at 3T Breast MRIhttps://www.pharmaradar360.com/article/promoting-physical-activity-and-reducing-sedentary-behavior-in-adults-with-type-e84257bf2f8ecbb7Pharma Surgeen2026-06-24T00:00:00.000ZPromoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trialhttps://www.pharmaradar360.com/article/drug-repurposing-of-sophoridine-for-sepsis-induced-organ-injury-from-in-depth-an-4bcd17ca73223be2Pharma Surgeen2026-06-24T00:00:00.000ZDrug repurposing of sophoridine for sepsis-induced organ injury: from in-depth analysis of a single agent to a multi-target therapeutic paradigmhttps://www.pharmaradar360.com/article/methodologies-for-generating-and-evaluating-clinical-and-performance-evidence-fo-ef640109401d5054Pharma Surgeen2026-06-24T00:00:00.000ZMethodologies for generating and evaluating clinical and performance evidence for high-risk and innovative medical devices and in vitro diagnostics: a scoping reviewhttps://www.pharmaradar360.com/article/bridging-the-theory-practice-gap-in-laboratory-medicine-development-and-applicat-b0c7f3f0f1e62cd1Pharma Surgeen2026-06-24T00:00:00.000ZBridging the theory-practice gap in laboratory medicine: development and application of a standardized case library for fostering clinical reasoning in postgraduate traininghttps://www.pharmaradar360.com/article/fd571a746e1226d9Pharma Surgeen2026-06-24T00:00:00.000ZГіперімуноглобулінемія Е як причина тяжкого хронічного інфекційного ураження шкіри: клінічний випадокhttps://www.pharmaradar360.com/article/bea11ce3a6d7af0aPharma Surgeen2026-06-24T00:00:00.000ZДезлоратадин у сучасній системі пероральної доставки ліків: вартий вибір для належного лікування алергічних захворюваньhttps://www.pharmaradar360.com/article/high-concordance-in-molecular-profiles-between-primary-tumors-and-matched-lymph-d9efdb0ab1933651Pharma Surgeen2026-06-24T00:00:00.000ZHigh Concordance in Molecular Profiles Between Primary Tumors and Matched Lymph Node Metastases in Differentiated Thyroid Carcinoma: Implications for Clinical Sample Selection